Table 1.
Baseline characteristics of patients with solid tumors and chronic viral hepatitis receiving ICIs (n = 33).
| Characteristic | Count (%) |
|---|---|
| Median age ± SD, years | 61.0 ± 8.7 |
| Sex | |
| Male | 27 (82%) |
| Female | 6 (18%) |
| Eastern Cooperative Oncology Group | |
| 0 | 8 (24%) |
| 1 | 19 (58%) |
| 2 | 3 (9%) |
| NA | 3 (9%) |
| Solid tumor type | |
| Hepatocellular carcinoma | 27 (82%) |
| Lung adenocarcinoma | 2 (6%) |
| Melanoma | 2 (6%) |
| Renal cell carcinoma | 2 (6%) |
| Cancer stage | |
| III | 5 (15%) |
| IV | 28 (85%) |
| Hepatitis diagnosis | |
| B | 10 (30%) |
| C | 23 (70%) |
| History of alcohol intake | |
| Positive | 11 (33%) |
| Negative | 21 (64%) |
| NA | 1 (3%) |
| Cirrhosis | |
| Yes | 28 (85%) |
| No | 5 (15%) |
| Child-Pugh score | |
| 5 | 18 (55%) |
| 6 | 5 (15%) |
| 7 | 3 (9%) |
| 8 | 2 (6%) |
| NA | 5 (15%) |
| Liver primary lesion/metastasis | |
| Yes | 28 (85%) |
| No | 5 (15%) |
| Number of prior lines | |
| 0 | 4 (12%) |
| 1 | 24 (73%) |
| 2 | 2 (6%) |
| ≥3 | 3 (9%) |
| Median number of comorbidities (range) | 2 (range 0-7) |
| ICI therapy type | |
| Anti-PD-1 monotherapy | 31 (94%) |
| Anti-PD-1 with anti-CTLA-4 | 2 (6%) |
| Anti-viral treatment | |
| Yes | 26 (79%) |
| No | 7 (21%) |
| HBV treatment concomitant to ICIs | 10 (100%) |
| HCV treatment* | 16 (70%) |
| Interferon based* | 6 (26%) |
| DAA based* | 10 (43%) |
Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; DAA, direct-acting antiviral; NA, not available; PD-1, programmed cell death protein-1.
*Among patients with HCV.